摘要
In a study published in Cell,Pozniak et al.explored the spectrum of the phenotypic cell states of human metastatic melanomas in their tumor microenvironment before and early during immune checkpoint inhibitor(ICI)therapy and identified an enrichment of mesenchymal-like(MES)state melanoma cells in non-responders to ICI.1 These findings offer valuable insights into the factors contributing to the refractoriness of certain melanoma patients to ICI,while also unveiling novel molecular targets that hold promise for improving their treatment outcomes.
